Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Overlook Medical Center
mi
from
Summit, NJ
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Overlook Medical Center
mi
from
Summit, NJ
Click here to add this to my saved trials
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Fairview Hospital Moll Pavilion Cancer Center
mi
from
Cleveland, OH
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Fairview Hospital Moll Pavilion Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Hillcrest Hospital
mi
from
Mayfield, OH
PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Hillcrest Hospital
mi
from
Mayfield, OH
Click here to add this to my saved trials
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Massacusetts General Hospital
mi
from
Boston, MA
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Massacusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Center for Cancer Research
mi
from
Bethesda, MD
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Center for Cancer Research
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cancer of the Uterus and Treatment of Stress Urinary Incontinence
Cancer of the Uterus and Treatment of Stress Urinary Incontinence
Status: Enrolling
Updated:  12/31/1969
Women and Infants Hospital
mi
from
Providence, RI
Cancer of the Uterus and Treatment of Stress Urinary Incontinence
Cancer of the Uterus and Treatment of Stress Urinary Incontinence
Status: Enrolling
Updated: 12/31/1969
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Reproductive Health Survivorship Care Plan
Intervening on Reproductive Health in Young Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
UC San Diego
mi
from
La Jolla, CA
Reproductive Health Survivorship Care Plan
Intervening on Reproductive Health in Young Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
UC San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Paul, MN
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
The Cancer Center at DeKalb Medical
mi
from
Decatur, GA
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
The Cancer Center at DeKalb Medical
mi
from
Decatur, GA
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Cadence Cancer Center
mi
from
Warrenville, IL
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Cadence Cancer Center
mi
from
Warrenville, IL
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Methodist Hospital
mi
from
Merrillville, IN
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Methodist Hospital
mi
from
Merrillville, IN
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Community Healthcare System
mi
from
Munster, IN
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Community Healthcare System
mi
from
Munster, IN
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Western Maryland Health System, Inc.
mi
from
Cumberland, MD
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Western Maryland Health System, Inc.
mi
from
Cumberland, MD
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Essex Oncology
mi
from
Belleville, NJ
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Essex Oncology
mi
from
Belleville, NJ
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma
mi
from
Oklahoma City, OK
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
St. Mary Medical Center
mi
from
Langhorne, PA
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
St. Mary Medical Center
mi
from
Langhorne, PA
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
St. Clair Hospital
mi
from
Pittsburgh, PA
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
St. Clair Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Desert Regional Medical Center
mi
from
Palm Springs, CA
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Desert Regional Medical Center
mi
from
Palm Springs, CA
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Women's Hospital
mi
from
Tampa, FL
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Women's Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Sparrow Cancer Center
mi
from
Lansing, MI
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Sparrow Cancer Center
mi
from
Lansing, MI
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Aurora Cancer Care
mi
from
Milwaukee, WI
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Aurora Cancer Care
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated:  12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
Status: Enrolling
Updated: 12/31/1969
Columbia - St. Mary's
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer
Phase 1 Trial and Randomized, Double-blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer
Phase 1 Trial and Randomized, Double-blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials